HBIO logo

HBIO Harvard Bioscience, Inc.

NASDAQ · Medical - Instruments & Supplies · Healthcare

$8.66
-0.02 (-0.23%)

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectroph…

Market Cap: $39.60Mwww.harvardbioscience.com

Price

No data yet.

Social Signal Score

56
5d
—
30d
57
3 mentions
—
60d
55
4 mentions
—
90d
55
4 mentions
—
news: 4

Analyst Ratings

6 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 2Sell 0Strong Sell 0
Avg price target$6-30.7%
Low $6Median $6High $6
Current Consensus

Revenue

$22.20M-15.97%
$20.45M$24.92M$29.39M$33.86M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$0.30
$0.30–$0.30
1 analysts
FY2026
$-1.02-439% YoY
$-1.02–$-1.01
2 analysts
FY2027
$-0.03
$-0.03–$-0.03
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
John D. Duke
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
328
Beta
1.47
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-2.66
www.harvardbioscience.com